Use of implanted gold fiducial markers with <scp>MV‐CBCT</scp> image‐guided <scp>IMRT</scp> for pancreatic tumours

Packard, Matthew; Gayou, Olivier; Gurram, Krishna C.; Weiss, Brandon; Thakkar, Shyam; Kirichenko, Alexander

doi:10.1111/1754-9485.12294

Cited by 10 publications

(6 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Without the fiducial marker, it is quite difficult to distinguish the pancreatic tumor from surrounding normal organs such as stomach and duodenum on cone beam CT for IGRT because of the movement or gas from gastrointestinal organs. Several reports demonstrated that marker matching is better than bony structure matching for pancreatic cancer [ 16 , 17 ]. Considering that the fiducial marker is beneficial to be implanted for IGRT for pancreatic radiotherapy if it is not DTT-IMRT, indispensability of fiducial marker for DTT-IMRT is not a specific weak point.…”

Section: Discussionmentioning

confidence: 99%

Clinical results of dynamic tumor tracking intensity-modulated radiotherapy with real-time monitoring for pancreatic cancers using a gimbal mounted linac

et al. 2018

View full text Add to dashboard Cite

ObjectivesWe performed dynamic tumor-tracking IMRT (DTT-IMRT) in locally advanced pancreatic cancer (LAPC) patients using a gimbaled linac of Vero4DRT. The purpose of this study is to report the first clinical results.MethodsFrom June 2013 to June 2015, eleven LAPC patients enrolled in this study and DTT-IMRT was successfully performed. The locoregional progression free survival (LRPFS), distant metastasis free survival (DMFS), overall survival (OS), hematologic and gastrointestinal (GI) toxicities were evaluated. Oncologic outcomes were estimated using Kaplan-Meier analysis, and toxicities using CTCAE v4.0.ResultsThe median radiation dose was 48 Gy (range, 45-51) in 15 fractions. Concurrent chemoradiotherapy (CCRT) was performed using gemcitabine in 9 patients and S-1 in one, while one patient refused. With a median follow-up of 22.9 months, 1-year LRPFS, DMFS, and OS rates were 90.9%, 70.7%, and 100%, respectively. Median survival time was 23.6 months. Grade-3 leucopenia and neutropenia were observed in two (18%) and one patient (9%), respectively. Grade-2 acute GI toxicity occurred in 2 patients (18%) and late grade-3 in 1 patient (9%).ConclusionsPreliminarily application of DTT-IMRT using a gimbaled linac on CCRT in LAPC patients resulted in excellent locoregional control and OS without severe toxicity.

show abstract

Section: Discussionmentioning

confidence: 99%

Clinical results of dynamic tumor tracking intensity-modulated radiotherapy with real-time monitoring for pancreatic cancers using a gimbal mounted linac

et al. 2018

View full text Add to dashboard Cite

show abstract

“…Taking into account the respiratory motion of the target mass during radiation therapy, the placement of fiducials has been related to better targeting compared with localization using adjacent bony anatomy. [ 16 17 ]…”

Section: The Role Of Radiation Therapy In Gastrointestinal Malignanciesmentioning

confidence: 99%

EUS-guided placement of fiducial markers for image-guided radiotherapy in gastrointestinal tumors: A critical appraisal

et al. 2021

View full text Add to dashboard Cite

We present here a new chapter of the series of papers on how to perform specific EUS techniques. In this manuscript, we discuss on how to perform EUS-guided placement of fiducial markers in gastrointestinal tumors. The aim is to present the scientific evidence of fiducials placement before radiation therapy, including an accurate revision of the literature, to give some advices on the technical approach, and to discuss Pros and Cons from the point of view of gastroenterologists and radiation oncologist.

show abstract

“…Studies have shown that fiducial markers improve the accuracy of target delineation during SBRT when compared with localization by the use of adjacent bony anatomy 9, 10, 11. Fiducial tracking is typically preferred when available.…”

Section: Role Of Fiducial Markers In Sbrtmentioning

confidence: 99%

EUS-guided placement of fiducial markers for the treatment of pancreatic cancer

et al. 2019

View full text Add to dashboard Cite

Use of implanted gold fiducial markers with MV‐CBCT image‐guided IMRT for pancreatic tumours

Cited by 10 publications

References 17 publications

Clinical results of dynamic tumor tracking intensity-modulated radiotherapy with real-time monitoring for pancreatic cancers using a gimbal mounted linac

Clinical results of dynamic tumor tracking intensity-modulated radiotherapy with real-time monitoring for pancreatic cancers using a gimbal mounted linac

EUS-guided placement of fiducial markers for image-guided radiotherapy in gastrointestinal tumors: A critical appraisal

EUS-guided placement of fiducial markers for the treatment of pancreatic cancer

Contact Info

Product

Resources

About